PHASE I ZIPRASIDONE IN SUBJECTS WITH NORMAL HEPATIC FUNCTION OR IMPAIRMENT

本研究的目的是比较口腔 齐拉西酮，一种正在研究的抗精神病药物，在稳定状态下， 肝功能不全受试者与正常受试者匹配 肝功能，并评价安全性、药代动力学和 齐拉西酮的耐受性。 齐拉西酮的药代动力学将 与安替比林相比，已知安替比林的代谢是 在肝硬化中受损 齐拉西酮正在被调查， 抗精神病药，因为它对多巴胺D2有很高的亲和力 受体的齐拉西酮还对5HT2受体具有高亲和力， 似乎具有较低的锥体外系副作用倾向。 齐拉西酮的耐受性可能比典型的精神抑制剂更好， 结合其作用机制，提供了继续 临床发展。

The purpose of the study is to compare the disposition of oral ziprasidone, an investigational antipsychotic agent, at steady state in subjects with hepatic dysfunction to matched subjects with normal hepatic function and to evaluate the safety, pharmacokinetics, and tolerability of ziprasidone. Ziprasidone pharmacokinetics will be compared to that of antipyrine, a drug whose metabolism in known to be impaired in cirrhosis. Ziprasidone is being investigated as an antipsychotic agent because of its high affinity for the dopamine D2 receptor. Ziprasidone also has a high affinity for 5HT2 receptors and appears to have a low extrapyramidal system side effect liability. Ziprasidone may be better tolerated than typical neuroleptics, which combined with its mechanism of action, provides the motive for continued clinical development.